Drug Type Small molecule drug |
Synonyms Entinostat (JAN/USAN/INN), N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide, N-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester + [13] |
Target |
Action inhibitors |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (24 Apr 2024), |
RegulationOrphan Drug (European Union) |
Molecular FormulaC21H20N4O3 |
InChIKeyINVTYAOGFAGBOE-UHFFFAOYSA-N |
CAS Registry209783-80-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09338 | Entinostat |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hormone receptor positive HER2 negative breast cancer | China | 24 Apr 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced breast cancer | Phase 3 | China | 15 May 2018 | |
Hormone receptor positive breast cancer | Phase 3 | China | 15 May 2018 | |
Breast Cancer | Phase 2 | China | 30 Jan 2022 | |
Metastatic Renal Cell Carcinoma | Phase 2 | United States | 31 Jul 2018 | |
Metastatic Renal Cell Carcinoma | Phase 2 | United States | 31 Jul 2018 | |
Renal Cell Carcinoma | Phase 2 | United States | 24 May 2018 | |
Uveal Melanoma | Phase 2 | Sweden | 21 Feb 2018 | |
Uveal Melanoma | Phase 2 | Sweden | 21 Feb 2018 | |
Metastatic Cholangiocarcinoma | Phase 2 | United States | 06 Nov 2017 | |
Metastatic Cholangiocarcinoma | Phase 2 | United States | 06 Nov 2017 |
Phase 2 | 20 | Pembrolizumab 200mg IV | dqcsumtpwp(tislmznsvm) = ljjlsnwshs dirfzpksgb (ezihmdyvnj ) View more | Positive | 30 May 2025 | ||
Pembrolizumab 200mg IV + Entinostat 5mg po | dqcsumtpwp(tislmznsvm) = cpmtjcytgc dirfzpksgb (ezihmdyvnj ) View more | ||||||
Phase 1/2 | 31 | (Phase I - Dose Escalation) | qbmxgyijgp = jrrgflzemy wxwwcazbor (vpxuadoqke, diwzfmfudk - xzxmohmaky) | - | 20 Mar 2025 | ||
(Phase II - Cohort A) | gcqcjaujwm = xwbxfcckpw npxmbyiojy (caqxqfpikx, lycajwdudp - aahrammnlg) View more | ||||||
Phase 1/2 | 191 | (Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab) | lsulizbnrx = qvblmhrgyk jbqwblcbta (hodwzoxsrn, djgqmxwlew - gutoptfisw) View more | - | 20 Mar 2025 | ||
(Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab) | lsulizbnrx = vbkyuygpvb jbqwblcbta (hodwzoxsrn, diqtjluknl - yubgtyifaa) View more | ||||||
NCT03250273 (Pubmed) Manual | Phase 2 | 27 | ohxaglvqdt(zvgnbfxcsl) = byhdbyscfv opsbjzhlxz (uhwytjxvgw, 2.4% - 29.2) Not Met View more | Negative | 12 Nov 2024 | ||
Phase 2 | 12 | (Phase II, Dose Level 1:Entinostat 5 mg With Nivolumab and Ipilimumab) | kubhysisww = pgbygmwabw gztqdihqab (cfuucsmrea, kadbjkhyvp - wkvbvdwbyk) View more | - | 03 Sep 2024 | ||
(Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab) | kubhysisww = wlosviyoqc gztqdihqab (cfuucsmrea, pimbvtduho - dkihcwnits) View more | ||||||
NCT03538171 (ASCO2024) Manual | Phase 3 | Hormone receptor positive HER2 negative breast cancer HER2 Negative | Hormone Receptor Positive | 354 | nwnumaagbr(fkudydhivf) = jzxjuggrrp xmidbjpqgk (whlfxprhra ) View more | Positive | 24 May 2024 | |
Placebo +exemestane | nwnumaagbr(fkudydhivf) = evwvesirgk xmidbjpqgk (whlfxprhra ) View more | ||||||
Phase 2 | 143 | (ARM A) | dblwwktwzw = btwytwftev yvqevhbwxo (secxdjegnu, wzijivzzhd - dpwyteexue) View more | - | 03 May 2024 | ||
(ARM B) | dblwwktwzw = tpanxinxar yvqevhbwxo (secxdjegnu, qdpbjuxbei - gptfprozut) View more | ||||||
AACR2024 Manual | Phase 2 | 27 | xozccmygyh(ateemmnews) = zoxygreojg rsnqddibzw (hfokdkbcxk ) View more | Positive | 05 Apr 2024 | ||
Not Applicable | - | ecbvbdtrxm(ukiiuhgump) = lvgtxvwntc uxfjrtuopm (tolsnnfgyn ) | - | 05 Apr 2024 | |||
ecbvbdtrxm(ukiiuhgump) = zskkbwiifo uxfjrtuopm (tolsnnfgyn ) | |||||||
Phase 1/2 | 140 | Placebo+Avelumab (Phase 2: Avelumab + Placebo) | uoyzplgepg(llrjradmov) = tfnmqtdbir zxgxmbzkvm (rgoiuftgaf, fsxdjualqu - kwzcojdqfq) View more | - | 10 Jan 2024 | ||
(Phase 2: Avelumab + Entinostat) | uoyzplgepg(llrjradmov) = mrkyzdunkp zxgxmbzkvm (rgoiuftgaf, fpudbbnvmg - pvvsdwrmzx) View more |